A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistant Candida albicans in vitro
Open accessAbstract
Candida albicans ( C. albicans ) is one of the most common clinical isolates of systemic fungal infection. Long-term and inappropriate use of antifungal drugs can cause fungal resistance, which poses a great challenge to the clinical treatment of fungal infections. The combination of antifungal drugs and non-antifungal drugs to overcome the problem of fungal resistance has become a research hotspot in recent years. Our previous study found that the combination of rifapentine (RFT) and fluconazole (FLC) has a significant synergistic against FLC-resistant C. albicans . The present study aimed to further verify the synergistic effect between FLC and RFT against the FLC-resistant C. albicans 100, and explore the underlying mechanism. The growth curve and spot assay test not only showed the synergistic effect of FLC and RFT on FLC-resistant C. albicans in vitro but exhibited a dose-dependent effect on RFT, indicating that RFT may play a principal role in the synergic effect of the two drugs. Flow cytometry showed that the combined use of RFT and FLC arrested cells in the G2/M phase, inhibiting the normal division and proliferation of FLC-resistant C. albicans . Transmission electron microscopy (TEM) demonstrated that FLC at a low concentration could still cause a certain degree of damage to the cell membrane in the FLC-resistant C. albicans , as represented by irregular morphologic changes and some defects observed in the cell membrane. When FLC was used in combination with RFT, the nuclear membrane was dissolved and the nucleus was condensed into a mass. Detection of the intracellular drug concentration of fungi revealed that the intracellular concentration of RFT was 31–195 fold that of RFT alone when it was concomitantly used with FLC. This indicated that FLC could significantly increase the concentration of RFT in cells, which may be due to the damage caused to the fungal cell membrane by FLC. In short, the present study revealed a synergistic mechanism in the combined use of RFT and FLC, which may provide a novel strategy for the clinical treatment of FLC-resistant C. albicans .
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antifungal resistance is rising, particularly against azole antifungals like fluconazole.
“Notably, recent studies report a rising prevalence of resistance, particularly against azole antifungals like fluconazole, widely regarded as a first‐line therapy [70].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 2× · see citing works
“Its antibacterial effect is mainly through inhibiting the synthesis of bacterial RNA and protein by competitive binding of DNA-dependent RNA polymerase β subunits and blocking the transcription of mRNA, ultimately leading to bacterial death [17,18].”
BackgroundAnalysis of Cell Cycle by Flow Cytometry
Pożarowski, P., & Darżynkiewicz, Z. (2004) · Humana Press eBooks · doi:10.1385/1-59259-811-0:301 · Cited by 587 · see citing works
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547 · see citing works
Fluconazole resistance in <em>Candida</em> species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542 · see citing works
Benator, D., Bhattacharya, M., Bozeman, L., Burman, W. J., Cantazaro, A., Chaisson, R. E., Gordin, F. M., Horsburgh, C. R., Horton, J., Khan, A., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09742-8 · Cited by 409 · see citing works
Self-citationThe evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311 · see citing works
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271 · see citing works
Morphogenesis and cell cycle progression in Candida albicans
Berman, J. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.10.007 · Cited by 237 · see citing works
Antifungals discovery: an insight into new strategies to combat antifungal resistance
Fuentefría, A. M., Pippi, B., Lana, D. F. D., Donato, K., & de Andrade, S. F. (2017) · Letters in Applied Microbiology · doi:10.1111/lam.12820 · Cited by 207 · see citing works
Toda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., et al. (2019) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6808a1 · Cited by 198 · cited 1× · see citing works
“…use of broad-spectrum antibiotics, glucocorticoids, immunosuppressants, and anti-tumor drugs in recent years, as well as large numbers of interventional diagnoses, treatments, and transplantation procedures, the incidence of clinical invasive Candida infections has been increasing yearly [1].”
BackgroundLiu, S., Hou, Y., Chen, X., Gao, Y., Li, H., & Sun, S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.12.009 · Cited by 148 · see citing works
Genesis of Azole Antifungal Resistance from Agriculture to Clinical Settings
Azevedo, M. M., Faria‐Ramos, I., Cruz, L., Pina‐Vaz, C., & Rodrigues, A. G. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b02728 · Cited by 134 · see citing works
da Silva, C. R., Neto, J. B. D. A., Campos, R. D. S., Figueiredo, N. S., Sampaio, L. S., Magalhães, H. I. F., Cavalcanti, B. C., Macêdo, D. S., de Andrade, G. M., Lima, I. S. P., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00651-13 · Cited by 130 · see citing works
Wu, X., Chang, W., Cheng, A., Sun, L., & Lou, H. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.01.001 · Cited by 129 · see citing works
Rifomycin, a new antibiotic; preliminary report.
Sensi, P., Margalith, P., & Mt, T. (1959) · PubMed · Cited by 116 · see citing works
Xiao, M., Chen, S. C.-A., Kong, F., Xu, X.-L., Yan, L., Kong, H.-S., Fan, X., Hou, X., Cheng, J.-W., Zhou, M.-L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz573 · Cited by 115 · see citing works
Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial
Dorman, S. E., Savić, R. M., GOLDBERG, S. V., Stout, J. E., Schluger, N. W., Muzanyi, G., Johnson, J. L., Nahid, P., Hecker, E. J., Heilig, C. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201410-1843oc · Cited by 110 · see citing works
Tyagi, A. K., & Malik, A. (2010) · Micron · doi:10.1016/j.micron.2010.05.007 · Cited by 106 · see citing works
Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species
Fothergill, A. W., Sutton, D. A., McCarthy, D. I., & Wiederhold, N. P. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03044-13 · Cited by 96 · see citing works
Combination Antifungal Therapy: A Review of Current Data
Campitelli, M., Zeineddine, N., Samaha, G., & Maslak, S. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2992w · Cited by 92 · see citing works
Antifungal Compounds againstCandidaInfections from Traditional Chinese Medicine
Liu, X., Ma, Z., Zhang, J., & Yang, L. (2017) · BioMed Research International · doi:10.1155/2017/4614183 · Cited by 92 · see citing works
Li, J. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1308 · Cited by 90 · see citing works
Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans
Liu, S., Yue, L., Gu, W., Li, X., Zhang, L., & Sun, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150859 · Cited by 87 · see citing works
Tadec, L., Talarmin, J., Gastinne, T., Bretonnière, C., Miegeville, M., Pape, P. L., & Morio, F. (2016) · Mycoses · doi:10.1111/myc.12470 · Cited by 79 · see citing works
Fluconazole Assists Berberine To Kill Fluconazole-Resistant Candida albicans
Li, D., Xu, Y., Zhang, D., Quan, H., Mylonakis, E. E., Hu, D., Li, M.-B., Zhao, L., Liang-hua, Z. H. U., Wang, Y., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00499-13 · Cited by 79 · see citing works
Self-citationAntibacterial activity of DL 473, a new semisynthetic rifamycin derivative.
Arioli, V., BERTI, M., CARNITI, G., Randisi, E., Rossi, E., & SCOTTI, R. (1981) · The Journal of Antibiotics · doi:10.7164/antibiotics.34.1026 · Cited by 77 · see citing works
Meintjes, G., Skolimowska, K. H., Wilkinson, K. A., Matthews, K., Tadokera, R., Conesa-Botella, A., Seldon, R., Rangaka, M. X., Rebe, K. B., Pepper, D. J., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0094oc · Cited by 75 · see citing works
Huang, S. H., Cao, Y., Dai, B. D., Sun, X. R., Zhu, Z., Cao, Y. B., Wang, Y., Gao, P. H., & Jiang, Y. Y. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2234 · Cited by 73 · see citing works
Self-citationShi, W., Chen, Z., Chen, X., Cao, L., Liu, P., & Sun, S. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00664.x · Cited by 72 · see citing works
Transcriptional Analysis of the <i>Candida albicans</i> Cell Cycle
Côte, P., Hogues, H., & Whiteway, M. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-03-0210 · Cited by 72 · see citing works
Mechanism of the Synergistic Effect of Amiodarone and Fluconazole in <i>Candida albicans</i>
Gamarra, S., Rocha, E. M. F., Zhang, Y.-Q., Park, S., Rao, R., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01728-09 · Cited by 70 · see citing works
Liu, W., Tan, J., Sun, J., Xu, Z., Li, M., Yang, Q., Shao, H., Zhang, L., Liu, W., Wan, Z., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt330 · Cited by 67 · see citing works
Self-citationHitchcock, C. A. (1991) · Biochemical Society Transactions · doi:10.1042/bst0190782 · Cited by 64 · see citing works
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Alfarisi, O., Alghamdi, W. A., Al‐Shaer, M. H., Dooley, K. E., & Peloquin, C. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1366311 · Cited by 63 · see citing works
Synergistic Action of Amphotericin Band Rifampin against Candida Species
Beggs, W. H., Sarosi, G. A., & Walker, M. I. (1976) · The Journal of Infectious Diseases · doi:10.1093/infdis/133.2.206 · Cited by 61 · see citing works
Scheven, M., & Schwegler, F. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1779 · Cited by 57 · see citing works
Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox
Kane, A., & Carter, D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040482 · Cited by 55 · see citing works
Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China
Liu, J.-Y., Shi, C., Wang, Y., Li, W.-J., Zhao, Y., & Xiang, M.-J. (2015) · Research in Microbiology · doi:10.1016/j.resmic.2015.02.009 · Cited by 54 · see citing works
Self-citationJia, W., Zhang, H., Li, C., Li, G., Liu, X., & Wei, J. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0728-1 · Cited by 53 · see citing works
Chloroquine sensitizes biofilms of Candida albicans to antifungal azoles
Shinde, R. B., Raut, J. S., Chauhan, N. M., & Karuppayil, S. M. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.11.002 · Cited by 47 · see citing works
Yong, J., Zu, R., Huang, X., Ge, Y., & Li, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01498 · Cited by 43 · see citing works
Gao, Y., Zhang, W., Lu, C., Liu, P., Li, Y., Li, H., & Sun, S. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12048 · Cited by 39 · see citing works
Díaz-García, J., Mesquida, A., Sánchez‐Carrillo, C., Reigadas, E., Muñóz, P., Escribano, P., & Guinea, J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01827-20 · Cited by 39 · see citing works
Rajasekharan, S. K., Lee, J.-H., & Lee, J. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.05.016 · Cited by 36 · see citing works
Zhang, M., Yan, H., Lü, M., Wang, D., & Sun, S. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.008 · Cited by 36 · see citing works
Proton pump inhibitors act synergistically with fluconazole against resistant Candida albicans
Lü, M., Yan, H., Yu, C., Yuan, L., & Sun, S. (2020) · Scientific Reports · doi:10.1038/s41598-019-57174-4 · Cited by 34 · see citing works
Li, X., Zhao, Y., Huang, X., Yu, C., Yang, Y., & Sun, S. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00124 · Cited by 33 · see citing works
Han, B., Chen, J., Yu, Y., Cao, Y., & Jiang, Y. (2016) · Microbiology and Immunology · doi:10.1111/1348-0421.12357 · Cited by 31 · see citing works
Self-citationGao, Y., Li, H. Z., Liu, S., Zhang, X., & Sun, S. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.072421-0 · Cited by 28 · see citing works
Recent trends in rifamycin research
Lal, R., & Lal, S. (1994) · BioEssays · doi:10.1002/bies.950160313 · Cited by 28 · see citing works
Clancy, C. J., Yu, Y. C., Lewin, A. S., & Nguyen, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.509 · Cited by 27 · see citing works
Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03158-4 · Cited by 26 · cited 1× · see citing works
“…non-steroidal anti-inflammatory drug ibuprofen [40], amlodipine and other four calcium channel blockers [41], lipid-lowering drug atorvastatin [42], anti-arrhythmia drug amiodarone [43], proton pump inhibitor omeprazole [44], phlegm-reducing drug ambroxol hydrochloride [45], and antipsychotic…”
BackgroundEl-Azizi, M. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46952-0 · Cited by 25 · see citing works
del Pozo, J. L., Francés, M. L., Hernáez, S., Serrera, A., Alonso, M. M., & Rubio, M. F. (2011) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000023 · Cited by 24 · see citing works
Zhu, B., Li, Z., Yin, H., Hu, J., Xue, Y., Zhang, G., Zheng, X., Chen, W., & Hu, X. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01478-21 · Cited by 24 · see citing works
Ibuprofen-Mediated Reversal of Fluconazole Resistance in Clinical Isolates of Candida
Sharma, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10094.5494 · Cited by 23 · see citing works
Reversal of azole resistance in Candida albicans by oridonin
Chen, H., Li, H., Duan, C., Song, C., Peng, Z., Li, H., & Shi, W. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.10.025 · Cited by 20 · see citing works
Reedy, J. L., Husain, S., Ison, M. G., Pruett, T. L., Singh, N., & Heitman, J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1573-1577.2006 · Cited by 18 · see citing works
Teymuri, M., Mamishi, S., Pourakbari, B., Mahmoudi, S., Ashtiani, M. T. K., Sadeghi, R. H., & Yadegari, M. H. (2015) · British Journal of Biomedical Science · doi:10.1080/09674845.2015.11666792 · Cited by 10 · see citing works
Wheatley, D. N., & Gray, L. H. (1988) · PubMed · Cited by 5 · see citing works
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [23]Wang Y.L. Zhang L.L. Qin Y.L. Cao Y.B. Jian-Hua W.U. Dermatology D.O. Hospital C. Synergistic effect of rifapentine with fluconazole against FLC-resistance Candida albicans Chinese Journal of Mycology 2016
Cited by
Sorted by citations
e Silva, D. M., de Souza Lacerda, L., de Souza Andrioli, A., Braz, W. R., Campos, L. M., de Paiva, M. R. B., Pittella, F., Fabri, R. L., & Tavares, G. D. (2025) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.70046 · Cited by 7 · see citing works
“Notably, recent studies report a rising prevalence of resistance, particularly against azole antifungals like fluconazole, widely regarded as a first-line therapy [70].”
Saeed, N. K., Almusawi, S., & Al‐Beltagi, M. (2024) · World Journal of Virology · doi:10.5501/wjv.v13.i4.98839 · Cited by 4 · see citing works
Hashempur, M. H., Radmanesh, A., Karami, F., Zomorodian, K., Amirzadeh, N., Shenavari, S., & Zareshahrabadi, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-09457-2 · Cited by 4 · see citing works
Madduri, M., Rudramurthy, S. M., & Roy, U. (2025) · ACS Omega · doi:10.1021/acsomega.5c06938 · Cited by 2 · see citing works
Queiroz, H. A., da Silva, L. J., Barroso, F. D. D., Sá, L. G. D. A. V., Neto, J. B. D. A., da Costa, É. R. M., de Oliveira, L. C., Barbosa, A. D., Cabral, V. P. D. F., Rodrigues, D. S., et al. (2024) · Future Microbiology · doi:10.1080/17460913.2024.2390286 · Cited by 2 · see citing works
Jimenez, D. L., da Silva, D. T. K., Sauda, T. D. P. C., de Almeida-Apolonio, A. A., Roque, E. P. O., de Castilho, P. F., dos Santos, J. V. D. A., Silva, S. M., Pizzuti, L., Amilcar, M., et al. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.112980 · Cited by 1 · see citing works
Jiang, L., Yang, L., Yang, L., Yang, B., Xing, L., Liu, J., Yan, R., Han, J., Li, G., & Wang, R. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117181 · Cited by 1 · see citing works
- Authors
- Wang, Y., He, Y., Cai, T., Lei, Z., Lei, W., Cao, Y., & Wu, J.
- Affiliations
- Second Military Medical University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Corresponding author
- Lei, Wenzhi
- Cao, Yongbing
- Wu, Jianhua
- Venue
- Heliyon
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 10
- Issue
- 6
- Pages
- e27346
- ISSN
- 2405-8440 (ISSN-L)
- PMC
- PMC10955295
- OpenAlex
- W4392368753
- Cited by
- 7
- References
- 62
- Citations by year
- 2025: 5 · 2024: 2
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Heliyon (publishedVersion, cc-by-nc-nd)
- SSRN Electronic Journal (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key Research and Development Program of China (2013CB531600)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- rifapentine, fluconazole, Candida albicans, antifungal resistance, synergistic drug combination, G2/M cell cycle arrest, cell membrane damage, intracellular drug accumulation, combination antifungal therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
